A clinical-stage biopharmaceutical company focused on discovering and developing precision medicines targeting biologically validated drivers of cancers and other diseases. The company's lead product candidate, OKI-219, is a selective PI3Ka inhibitor in Phase 1 clinical trials for treating solid tumors including breast cancer.